Speeches by Bryant.

“What do you know?”

“The right hon. Gentleman refers to all the happy days he had, but I do not think that he really enjoyed the Report stage of the previous Bill. I think—nobody else will notice if he admits it here now—that he did not really like everything that was in the previous Government’s version of the Bill, and that he rather pre…”

“I think the hon. Gentleman needs to speak to the hon. Member who spoke earlier—oh, he’s left. I actually believe that the vaccines saved lives; I do not believe that they lost people their lives. I am afraid that the hon. Gentleman and I will never be united on that front.”

“It is good to hear from the Chair of the Select Committee. I want to make it absolutely clear that AstraZeneca is not leaving—people are not losing their jobs because of this decision. There are still 10,000 people employed by AstraZeneca in the UK and, for that matter, it is proceeding with its nasal-based flu vaccine…”

“Thank you, Mr Speaker. And £14 billion was secured following the announcement of our artificial intelligence opportunities plan. We have cut the rate of corporation tax to 25%, which is the lowest in the G7. We are creating a pension mega-fund to be able to invest further. According to PricewaterhouseCoopers’ last CEO …”

“What utter nonsense. We endured 14 years of growth that even the shadow Minister’s own Back Benchers used to describe as anaemic and feeble. Average growth under Tory Governments is 1.2%; average growth under Labour Governments is 2.4%. We are far more likely to secure growth in the British economy under a Labour Gover…”

“As the largest company listed on the London Stock Exchange, employing more than 10,000 people and investing about £2.5 billion every year in the UK, AstraZeneca is a close and valued partner to this Government and is critical to the UK’s thriving life sciences sector. We saw that in the covid-19 pandemic, when AstraZen…”

“That is the cleverest bid for finance that I have ever heard, so my hon. Friend gets an award for that. She is right that we stand ready at any point to assist key investments of this nature, especially in the life sciences sector. The difference between the amount of money that was theoretically made available by the …”

“The right hon. Lady puts it in a particular way, but it is not a way that is consonant with the facts. The fact is that this deal had not been signed or got over the line by the previous Government, who, as I have said, would quite often announce things and not actually deliver in the end. In spring 2024, the then Chan…”

“Yes, 100%. I know that my hon. Friend has visited AstraZeneca and spoken to it many times. He is absolutely right to note that there are, I think, 4,000 working at the Macclesfield site, and will continue to do so. I am sure that AstraZeneca has a very strong future in Macclesfield. Nothing in this decision changes tha…”

“Not necessarily for this specific deal, but certainly for a deal with AstraZeneca, yes.”

“I would be delighted to meet my hon. Friend knows, as she knows, although I think it would probably be more useful for her if she were to meet Lord Vallance, who is the Minister for life sciences. My hon. Friend is absolutely right; we would of course much prefer this investment to go ahead and to have been able to get…”

“It is almost sad, sometimes. I just wish the hon. Member had been here for the last 14 years. I wish he had been here when we had endless strikes in every single part of every Department and we could not get the NHS waiting lists dealt with because we were not paying our nurses and our doctors properly. The first thing…”

“First, let me clear up a point about national insurance contributions. I know that the Conservative party likes to bang on about them, but many people do not know that 50% of businesses and organisations in the UK will pay either exactly the same amount of national insurance or less. That fact is not often, if ever, re…”

“The hon. Lady’s first point was on the voluntary scheme for branded medicines pricing and access, which is reduced to an acronym that is not really an acronym: VPAG. This is, as it says on the tin, a voluntary agreement between Government, the pharmaceutical industry and the NHS, which is designed specifically to ensur…”

“If I might just refer to the first comment first, I am the Member for Rhondda and Ogmore, so I fully understand that investment in one part of the country is obviously great for that part of the country, but it does not necessarily mean that every part of the country is rising with everybody else. Trying to make sure t…”

“No.”

“Not only have we set aside £520 million precisely to be able to invest in the life sciences industry with an innovation fund, we are very keen to work with specific businesses to understand how they can make more secure, long-term investment. The single most important thing for most people making an investment in the U…”

“The thing is that spending taxpayers’ money has to be proven to be good value for money. That is why, whenever we are making an investment such as this, we have to make sure it delivers more return on investment than £1 for £1. When AstraZeneca made the decision to cut the R&D part of its budget from £150 million t…”

“There are all sorts of bids coming in now, none of which I am in charge of, but we have seen significant added investments in the UK since the autumn. For instance, Iberdrola is doubling its investment through Scottish Power from £12 billion to £24 billion over the next four years, and Blackstone has confirmed a £10 bi…”